Prevention of recurrent myocardial infarction and sudden death with aspirin therapy.
In October 1985, the Food and Drug Administration approved a new indication of aspirin for the secondary prevention of recurrent myocardial infarction (MI) and death in patients with MI or unstable angina. Clinical trials have demonstrated the efficacy of this drug, especially when treatment is begun soon after the initial event. The antiplatelet actions of aspirin seem to be the most plausible explanation for its efficacy in reducing mortality and the rate of reinfarction. A single daily 325-mg tablet is effective and produces side-effect incidences of only zero to two percent above those produced by placebo. This article assesses the current state of knowledge regarding the value of aspirin therapy in survivors of acute MI and the implications for clinical practice.
Rumore
M M
MM
Professional Services Department, Sterling Drug Inc., New York, NY 10016.
Goldstein
G S
GS
D001241:Aspirin / Q000627:therapeutic use*; D003645:Death, Sudden / Q000517:prevention & control; D006801:Humans; D009203:Myocardial Infarction / Q000401:mortality / Q000517:prevention & control*; D011379:Prognosis; D012008:Recurrence
D001241:Aspirin